FDC Ltd

FDC, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical parameters, reflecting a change in price momentum and market sentiment. Recent data reveals a transition from mildly bearish to bearish technical trends, with several indicators signalling adjustments in the stock’s evaluation.

FDC, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a technical event where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend, indicating potential long-term weakness and trend deterioration for the stock.

FDC, a small-cap pharmaceutical company, reported a challenging quarter ending September 2025, with net sales declining significantly and profit after tax dropping sharply. Despite achieving its highest operating cash flow, the company faces low return on capital employed and has underperformed against the Sensex over the past year.

FDC Ltd, a small-cap pharmaceutical company, experienced a significant decline in stock price, continuing a downward trend over recent days. The stock is trading below key moving averages and has shown high volatility, with technical indicators suggesting a bearish outlook. Its performance contrasts sharply with the broader market.

FDC Limited, a prominent integrated pharmaceutical company with a market capitalisation of ₹6,684.98 crores, reported a concerning performance in Q2 FY26, with consolidated net profit plunging 76.62% quarter-on-quarter to ₹28.37 crores from ₹121.35 crores in Q1 FY26. On a year-on-year basis, net profit declined 60.62% from ₹72.04 crores in Q2 FY25. The stock reacted sharply to the disappointing results, falling 8.26% to ₹410.60, reflecting investor concerns about the company's near-term prospects and operational challenges.

FDC Ltd, a small-cap pharmaceutical company, has faced significant losses, with shares declining for two consecutive days. The stock has underperformed against the broader market, showing a year-to-date decline. Currently, it trades below key moving averages, indicating a challenging market position amid ongoing developments.

FDC, a small-cap pharmaceutical and biotechnology firm, has experienced mixed technical performance, with bearish indicators on weekly and monthly charts, while daily metrics show mild bullishness. Despite recent fluctuations, FDC has outperformed the Sensex over the past week and three years, but struggles in one-year and five-year comparisons.

FDC, a small-cap pharmaceutical company, has recently adjusted its evaluation, reflecting a shift in market sentiment. The company reported a significant profit before tax of Rs 124.28 crore and achieved record net sales of Rs 648.41 crore, despite facing long-term growth challenges and underperforming against market benchmarks.

FDC, a small-cap pharmaceutical company, has recently revised its evaluation amid mixed market signals. While it has faced a -16.13% return over the past year, it shows resilience with a 48.64% return over three years, though it lags behind the Sensex's five-year performance.

FDC, a small-cap pharmaceutical company, has recently revised its evaluation amid market fluctuations. Despite a challenging year with a negative return, its three-year performance has outpaced the Sensex. Technical indicators present mixed signals, reflecting the company's ongoing adaptation to the evolving industry landscape.